Univariate analyses of demographics based on symptomatic intracranial haemorrhage (sICH)
| No sICH | sICH | P values | |
| 559 (96.7%) | 19 (3.3%) | ||
| Age (years) (mean, SD) | 72.6±15.1 | 71.2±14.2 | 0.695 |
| Sex (% female) | 293 (52.4%) | 9 (47.4%) | 0.665 |
| Diabetes (%) | 127 (22.7%) | 8 (42.1%) | 0.152 |
| Glucose (mg/dL) (mean, SD) | 137.2±57.9 | 162.2±74.8 | 0.067 |
| Hypertension (%) | 425 (76%) | 16 (84.2%) | 0.585 |
| Atrial fibrillation (%) | 280 (50.2%) | 6 (31.6%) | 0.111 |
| INR (median, IQR) | 1 (1–1) | 1 (1–1) | 0.582 |
| Antiplatelet therapy (%) | 252 (45.1%) | 9 (47.4%) | 0.844 |
| Anticoagulation therapy (%) | 92 (16.5%) | 2 (10.5%) | 0.752 |
| Platelet (mean, SD) | 215±74 | 220±57 | 0.778 |
| ASPECTS (median, IQR) | 10 (9–10) | 9 (7–10) | 0.068 |
| NIHSS score (median, IQR) | 17 (12–22) | 15 (12–22) | 0.766 |
| Site of occlusion | 0.535 | ||
| ICA (%) | 94 (16.8%) | 1 (5.3%) | |
| M1 (%) | 346 (61.9%) | 15 (78.9%) | |
| M2 (%) | 79 (14.1%) | 2 (10.5%) | |
| Basilar (%) | 40 (7.2%) | 1 (5.3%) | |
| Alteplase (%) | 293 (52.4%) | 12 (63.2%) | 0.356 |
| mTICI post-procedure (median, IQR) | 4 (3–5) | 4 (3–5) | 0.1 |
| mTICI post-procedure≥2b (%) | 479 (47.4%) | 10 (52.6%) | 0.001 |
| Onset to recanalisation (mean, SD) | 375±397 | 402±378 | 0.791 |
| 90-day mRS (median, IQR) | 3 (2–6) | 6 (4–6) | <0.001 |
ASPECTS, Alberta stroke program early CT score; ICA, internal carotid artery; INR, international normalized ratio; M1, M1 segment of the middle cerebral artery; M2, M2 segment of the middle cerebral artery; NIHSS, National Institute of Stroke Scale; mRS, modified Rankin scale; mTICI, modified thrombolysis in cerebral infarction.